Abstract Library

#2001 The Anticancer Mechanism of Metformin in Pancreatic Neuroendocrine Tumor Cells

Introduction: Metformin, a widely used antidiabetic drug, has been reported to display potent anticancer properties in various types of cancers. In P-NETs, aryl hydrocarbon receptor-interacting protein (AIP) acts as a tumor suppressor and is up-regulated by the somatostatin analog octreotide.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Lania A

Authors: Vitali E, Piccini S, Boemi I, Brambilla T, Zerbi A,

Keywords: GEP-NET, Metformin, AIP,

#1658 The Clinical Significance of Elevated Serum Procalcitonin in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms

Introduction: Elevated serum procalcitonin (PCT) was reported in some patients with neuroendocrine neoplasms (NEN), but its clinical significance in gastroenteropancreatic NEN (GEP-NEN) was still unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Chen L

Authors: Chen L, Zhang Y, Chen M, Chen J,

Keywords: procalcitonin, neuroendocrine neoplasms, tumor grade, survival,

#1081 High Thyrocalcitonin Serum Level in Neuroendocrine Tumors: Characteristics, Prognosis and Interest in Follow-Up?

Introduction: Thyrocalcitonin (TCT) is usually associated with medullary thyroid cancer. However, some neuroendocrine tumors (NETs) have also high serum TCT levels.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Nozière C, Chardon L, Lombard-Bohas C, Goichot B, Hervieu V,

Keywords: thyrocalcitonin,

#854 Scoping Study on Quality of Life (QL) in Patients (pts) with Neuroendoncrine Tumors (NET) of the Digestive Tract in Argentina: Preliminary Results

Introduction: Patients with NET compound a specific cancer population: their survival used to be longer than other cancer patient populations and they received drugs (eg. somatostatin analogues) rarely used on others. The systematic measure of QL in these patients could lead to better understanding of the impact of the disease and treatments, not only in terms of symptom prevalence but also in relation to daily concerns.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: PESCE V

Authors: Grance G, Pesce V, Bestanti C, O'Connor J, Roca E,

Keywords: NET, quality of life, symptom burden, supportive care,

#89 Hyperplasia-adenoma sequence in pituitary carcinogenesis: new insight into the role of AIP gene

Introduction: Pituitary adenoma predisposition has been recently associated with germline mutations in the Aryl-Hydrocarbon Receptor Interacting Protein (AIP) gene. This association has been detected in familial and, more rarely, in sporadic cases. The mechanisms by which the AIP mutations promote pituitary adenoma development remain unknown.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Villa C

Authors: Villa C, Lagonigro M, Magri F, Brauner R, Bouligand J,

Keywords: AIP gene, pituitary hyperplasia-adenoma sequence ,